Micron (MU) plans to roughly double its HBM production capacity to about 100,000 wafers per month by year-end, ET reports
Newsquawk Staff ·
Micron (MU) plans to roughly double its HBM production capacity to about 100,000 wafers per month by year-end, ET reports.
What it means
Capacity announcements in high-bandwidth memory have become the recurring battleground of the AI buildout, and each of the three HBM producers has used staged expansion headlines to signal commitment to share in what has been a supply-constrained market. Historically, the sequence in memory is well worn: tight supply and elevated pricing, aggressive wafer additions from all suppliers, then the question of whether demand absorbs the new bit supply or the cycle reverts to the oversupply pattern that has defined commodity DRAM for decades. The relevant distinction here is HBM versus conventional memory: HBM carries long qualification cycles, advanced packaging bottlenecks, and contracted volumes, so wafer capacity does not translate directly into sellable supply, and yield rather than nameplate capacity has been the binding constraint in past ramps. For Micron specifically, the tell is how much of the new output is already committed under customer agreements versus speculative, since uncommitted capacity reads differently for pricing. The follow-ons are peer responses on their own HBM roadmaps, customer qualification milestones, and any commentary on bit supply growth versus demand in upcoming earnings calls.
Sources
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS
- Newsquawk Weekly Economic Release 26th - 30th October 2026
Related headlines
- OpenAI reveals plans for an in-house exabyte-scale storage system11 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter11 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)12 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed12 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce13 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders14 hours ago
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease7 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL9 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 202711 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability12 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer14 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation14 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM14 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years15 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months16 hours ago